Proceeding contribution from Adam Afriyie (Conservative) in the House of Commons on Thursday, 8 December 2005. It occurred during Estimates day on Department of Health.
Department of Health
: I thank the hon. Lady for giving way before she moves to her final, final point. She focused on costs, but does she agree that although the work that NICE does is very important, it is also important that it be done quickly? In many cases, it is a matter of life and death as to whether or not a particular drug gets to the patient quickly. Does she also share my concern at the fact that, rather than the budget increasing, it has just been reduced by £3.5 million? That will surely cause more problems than even the difficulties relating to Herceptin.
Secondary information
- Type
- Proceeding contribution
- Reference
- 440 c1033
- Session
- 2005-06
- Chamber / Committee
- House of Commons chamber
- Subjects
- Advertising Licensing Expenditure Drugs Government departments Industry Prescription drugs Department of Health Medicines and Healthcare products Regulatory Agency Research Regulation Safety National Institute for Health and Care Excellence Registration Clinical trials
- Link
- View this Proceeding contribution on www.publications.parliament.uk
Librarians' tools
- Timestamp
- 2025-11-24 15:50:34 +0000
- URI
- http://data.parliament.uk/pimsdata/hansard/CONTRIBUTION_285114
- In Indexing
- http://indexing.parliament.uk/Content/Edit/1?uri=http://data.parliament.uk/pimsdata/hansard/CONTRIBUTION_285114
- In Solr
- https://search.parliament.uk/claw/solr/?id=http://data.parliament.uk/pimsdata/hansard/CONTRIBUTION_285114